2023
Mineral bone disorder in children with chronic kidney disease: Data from the KNOW-Ped CKD (Korean cohort study for outcome in patients with pediatric chronic kidney disease) study
Jung J, Lee K, Park E, Park Y, Kang H, Ahn Y, Ha I, Kim S, Cho H, Han K, Cho M, Choi H, Lee J, Shin J. Mineral bone disorder in children with chronic kidney disease: Data from the KNOW-Ped CKD (Korean cohort study for outcome in patients with pediatric chronic kidney disease) study. Frontiers In Pediatrics 2023, 11: 994979. PMID: 36873652, PMCID: PMC9982157, DOI: 10.3389/fped.2023.994979.Peer-Reviewed Original ResearchChronic kidney disease stageFractional excretion of phosphateMineral bone disorderChronic kidney diseasePediatric CKD patientsIntact parathyroid hormoneVitamin DSerum phosphateCKD patientsFGF-23Levels of 1,25-dihydroxy vitamin DUrine calcium-to-creatinine ratioMedian serum calcium levelBone disordersKidney diseaseSerum intact parathyroid hormoneCalcium to creatinine ratioChronic kidney disease stage 3bZ-scorePrevalence of hyperphosphatemiaSerum calcium levelsSerum vitamin DActive vitamin DFibroblast growth factor 23Abnormal mineral metabolism
2021
FGF-23 (Fibroblast Growth Factor-23) and Cardiorenal Interactions
Ivey-Miranda JB, Stewart B, Cox ZL, McCallum W, Maulion C, Gleason O, Meegan G, Amatruda JG, Moreno-Villagomez J, Mahoney D, Turner JM, Wilson FP, Estrella MM, Shlipak MG, Rao VS, Testani JM. FGF-23 (Fibroblast Growth Factor-23) and Cardiorenal Interactions. Circulation Heart Failure 2021, 14: e008385. PMID: 34689571, PMCID: PMC8782627, DOI: 10.1161/circheartfailure.121.008385.Peer-Reviewed Original ResearchConceptsFGF-23Cardiorenal interactionsHeart failureDiuretic resistanceSodium avidityNeurohormonal activationMultivariable analysisDistal tubular sodium reabsorptionLoop diuretic doseTubular sodium reabsorptionGlomerular filtration rateCardiorenal dysfunctionDiuretic doseDiuretic treatmentNT-proBNPFractional excretionDiuretic administrationSodium reabsorptionPeak diuresisFiltration rateCare centerUrine samplingAnimal modelsSerum chlorideDisease severity
2020
SUN-333 Burosumab Improves Bone Density in Patients with X-Linked Hypophosphatemia
Murari K, Insogna K. SUN-333 Burosumab Improves Bone Density in Patients with X-Linked Hypophosphatemia. Journal Of The Endocrine Society 2020, 4: sun-333. PMCID: PMC7207437, DOI: 10.1210/jendso/bvaa046.1470.Peer-Reviewed Original ResearchTrabecular bone scoreBone mineral densityL-spine bone mineral densityTotal hip bone mineral densityHip bone mineral densityBone scorePhase III clinical trialsRegional bone mineral densityRenal phosphate leakCourse of treatmentHuman monoclonal antibodyConsiderable clinical relevanceSignificant increaseFGF-23Frequent siteClinical trialsMineral densityMineral metabolismBone densityDrug treatmentPhosphate leakBurosumabBMD measurementsClinical relevanceStudy subjectsIL‐1β Drives Production of FGF‐23 at the Onset of Chronic Kidney Disease in Mice
McKnight Q, Jenkins S, Li X, Nelson T, Marlier A, Cantley LG, Finberg KE, Fretz JA. IL‐1β Drives Production of FGF‐23 at the Onset of Chronic Kidney Disease in Mice. Journal Of Bone And Mineral Research 2020, 35: 1352-1362. PMID: 32154933, PMCID: PMC7363582, DOI: 10.1002/jbmr.4003.Peer-Reviewed Original ResearchConceptsChronic kidney diseaseOnset of CKDEarly chronic kidney diseaseFGF-23 expressionFGF-23Renal dysfunctionParathyroid hormoneIL-1βCongenital chronic kidney diseaseFGF-23 levelsSerum parathyroid hormoneGlomerular capillary tuftCongenital modelSerum phosphateIron bioavailabilitySystemic elevationVitamin DInflammatory cytokinesKidney diseaseEarly biomarkersIron statusMouse modelPhosphate imbalanceInitial upregulationCapillary tuft
2019
FGF-23 and Cardio-Renal Interactions in Heart Failure
Stewart B, Gomez N, Barnett J, Thomas A, Wycallis E, Pattoli M, Struyk G, Fleming J, Shamlian P, Raghavendra P, Mahoney D, Ivey-Miranda J, Griffin M, Rao V, Testani J. FGF-23 and Cardio-Renal Interactions in Heart Failure. Journal Of Cardiac Failure 2019, 25: s23-s24. DOI: 10.1016/j.cardfail.2019.07.545.Peer-Reviewed Original ResearchCardio-renal dysfunctionFGF-23 levelsFGF-23NT-proBNPDiuretic responsivenessIL-6Outpatient heart failure (HF) patientsPlasma FGF-23 levelsFibroblast growth factor 23Adverse left ventricular remodelingCardio-renal interactionsHigher NT-proBNPTotal renin levelsPlasma IL-6Heart failure patientsRenal sodium retentionGrowth factor 23High plasma reninLeft ventricular remodelingInduction of inflammationStrong independent associationResults Higher levelsDiuretic doseNeurohormonal activationPhosphaturic hormone
2014
Mineral and Bone Disorder in Children with Chronic Kidney Disease Stage I to V (Predialysis)
Lee J, Kang H, Cho H, Shin J, Cho M, Park Y, Ha I, Cheong H, Ahn C. Mineral and Bone Disorder in Children with Chronic Kidney Disease Stage I to V (Predialysis). Kidney Research And Clinical Practice 2014, 33: a3-a4. DOI: 10.1016/j.krcp.2014.05.021.Peer-Reviewed Original ResearchIntact parathyroid hormoneChronic kidney diseaseAdvanced chronic kidney diseaseBone disordersSerum phosphorusFGF-23Serum intact parathyroid hormoneSerum FGF-23 levelsChronic kidney disease stages I–VFibroblast growth factor (FGF)-23Increased alkaline phosphatase levelsPrevalence of hyperparathyroidismPrevalence of hyperphosphatemiaCalcium x phosphorusFGF-23 levelsGlomerular filtration ratePediatric nephrology centersPrevalence of patientsUrinary phosphorus excretionAlkaline phosphatase levelsKNOW-CKDUrine phosphorusParathyroid hormoneCKD-mineralNephrology centersFibroblast Growth Factor-23, Cardiovascular Prognosis, and Benefit of Angiotensin-Converting Enzyme Inhibition in Stable Ischemic Heart Disease
Udell J, Morrow D, Jarolim P, Sloan S, Hoffman E, O'Donnell T, Vora A, Omland T, Solomon S, Pfeffer M, Braunwald E, Sabatine M. Fibroblast Growth Factor-23, Cardiovascular Prognosis, and Benefit of Angiotensin-Converting Enzyme Inhibition in Stable Ischemic Heart Disease. Journal Of The American College Of Cardiology 2014, 63: 2421-2428. PMID: 24727254, PMCID: PMC4213068, DOI: 10.1016/j.jacc.2014.03.026.Peer-Reviewed Original ResearchConceptsStable ischemic heart diseaseAngiotensin-Converting Enzyme Inhibitor TherapyEnzyme inhibitor therapyFGF-23 levelsRenal functionFGF-23Clinical benefitIncident heart failureHeart failureIschemic heart diseaseCardiovascular deathInhibitor therapyCardiovascular biomarkersBenefit of angiotensin-converting enzyme inhibitionIncreased risk of cardiovascular deathLeft ventricular ejection fractionMarkers of renal functionHeart diseaseAssociated with cardiovascular deathFibroblast growth factor (FGF)-23Risk of cardiovascular deathVentricular ejection fractionAngiotensin-Converting Enzyme InhibitionAssociated with cardiovascular eventsFibroblast growth factor 23
2012
Chapter 26 Familial Hypophosphatemia and Related Disorders
Holm I, Econs M, Carpenter T. Chapter 26 Familial Hypophosphatemia and Related Disorders. 2012, 699-726. DOI: 10.1016/b978-0-12-382040-2.10026-7.Peer-Reviewed Original ResearchAutosomal dominant hypophosphatemic ricketsTumor-induced osteomalaciaRelated disordersClinical featuresHypophosphatemic ricketsPathophysiology of XLHLong-term morbidityDevelopment of ricketsDegenerative joint diseaseHereditary hypophosphatemic ricketsCommon bone diseaseDominant hypophosphatemic ricketsFGF-23Joint painDental abscessDihydroxyvitamin DAvailable therapiesFamilial hypophosphatemiaHypophosphatemic diseasesDental diseaseJoint diseaseBone diseaseChronic featuresTherapeutic approachesRenal phosphate
2009
Survey of the Enthesopathy of X-Linked Hypophosphatemia and Its Characterization in Hyp Mice
Liang G, Katz LD, Insogna KL, Carpenter TO, Macica CM. Survey of the Enthesopathy of X-Linked Hypophosphatemia and Its Characterization in Hyp Mice. Calcified Tissue International 2009, 85: 235-246. PMID: 19609735, PMCID: PMC2988401, DOI: 10.1007/s00223-009-9270-6.Peer-Reviewed Original ResearchMeSH KeywordsAchilles TendonAdolescentAdultAgedAnimalsBiomarkersCalcinosisChildDisease Models, AnimalDisease ProgressionFamilial Hypophosphatemic RicketsFemaleFibroblast Growth Factor-23Fibroblast Growth FactorsGenetic Diseases, X-LinkedHumansMiceMice, Inbred C57BLMiddle AgedPatellar LigamentPhenotypeQuadriceps MuscleRadiographyRheumatic DiseasesTendinopathyTendonsYoung AdultConceptsFGF-23Fibroblast growth factor receptor 3Hyp miceMajority of patientsHigh circulating levelsPhosphate-regulating hormoneBone spur formationTendon insertion siteGrowth factor receptor 3Insertion siteLigament insertion sitesCirculating LevelsPhosphate excretionBone-forming osteoblastsHeterotopic calcificationOsteophyte formationHistological examinationMurine modelReceptor 3Spur formationHypophosphatemiaEnthesis fibrocartilageBone mineralizationBiochemical milieuMice
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply